Welcome to our dedicated page for Zai Lab American Depositary Shares news (Ticker: ZLAB), a resource for investors and traders seeking the latest updates and insights on Zai Lab American Depositary Shares stock.
Zai Lab Limited (NASDAQ: ZLAB) is a pioneering biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines. Established in 2013 by industry veterans, Zai Lab addresses some of the world's most pressing unmet medical needs with a vision to transform patients’ lives globally.
The company employs a dual approach of in-licensing products and internal research and development to maintain a robust pipeline. This strategy has led to the development of promising drug candidates aimed at treating a range of severe health conditions, particularly in oncology, autoimmune, and infectious diseases.
Core Products and Pipeline:
- ZL-2306: An investigational treatment for multiple solid tumor types, including ovarian, breast, and lung cancers.
- ZL-2401: A novel antibiotic belonging to a new class of tetracycline derivatives, significant in the battle against resistant bacterial infections.
- ZL-2301: An oral small molecule targeting hepatocellular carcinoma (HCC), promising for liver cancer treatment.
Zai Lab's leadership team is acclaimed for their innovative regulatory approval pathways in China, which have expedited the introduction of new therapies. The company's partnerships with global pharmaceutical giants underscore its commitment to conducting world-class clinical development both in China and internationally.
Financially, Zai Lab has strong support from a cadre of leading healthcare investors, ensuring robust backing for its ambitious projects. This financial stability allows the company to explore cutting-edge research and expand its therapeutic offerings continually.
Recent Achievements and Current Projects:
- Successful initiation of multiple late-stage clinical trials across various therapeutic areas.
- Establishment of strategic partnerships with multinational pharmaceutical companies to enhance drug development and commercialization.
- Ongoing expansion of their research facilities to accommodate new projects and collaborations.
Zai Lab remains committed to leveraging its expertise, innovation, and strategic partnerships to bring life-changing therapies to market, ultimately improving patient outcomes worldwide.
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced the acceptance of their New Drug Application (NDA) for sulbactam-durlobactam (SUL-DUR) by China's National Medical Products Administration (NMPA). This investigational drug targets Acinetobacter baumannii infections, particularly multidrug-resistant and carbapenem-resistant strains, addressing a significant medical need. The drug shows promise in reducing mortality and renal toxicity over standard colistin therapy. SUL-DUR has also received priority review status in both China and the U.S. Zai Lab holds exclusive development rights for SUL-DUR in multiple countries across Asia and Oceania.
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced it will report financial results for the twelve months ended December 31, 2022, after U.S. market closure on March 1, 2023. A live conference call and webcast will take place on March 2, 2023, at 8:00 a.m. ET. Investors can access the webcast via the company's website, and advance registration is required. This event will highlight the company's progress and future direction in the biopharmaceutical sector, particularly in oncology, autoimmune disorders, infectious diseases, and neurological disorders.
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced its participation in several investor conferences in February 2023. Key events include a fireside chat at the Guggenheim Oncology Conference on February 8, and two chats on February 14 at the SVB Securities Global Biopharma Conference and the Citi Biotech C-Suite Fireside Chat Series. Interested parties can access the webcast links in the Investor Relations section of Zai Lab's website. The company aims to deliver transformative medicines for oncology, autoimmune disorders, infectious diseases, and neurological disorders globally.
Zai Lab Limited (NASDAQ: ZLAB) announced that China's Center for Drug Evaluation (CDE) has granted priority review status to the New Drug Application (NDA) for sulbactam-durlobactam (SUL-DUR). This investigational drug targets infections by Acinetobacter baumannii, especially multidrug-resistant strains. The grant emphasizes the urgent need for new treatments in light of the high mortality rates associated with these infections in ICU settings. The FDA has also accepted the NDA for SUL-DUR for priority review, with an action date of May 29, 2023. Zai Lab holds exclusive commercialization rights for SUL-DUR in multiple Asia-Pacific regions.
Zai Lab Limited (NASDAQ: ZLAB) announced that its drugs QINLOCK® (ripretinib) and NUZYRA® (omadacycline) have been added to China's National Reimbursement Drug List (NRDL). This inclusion is significant for patients with advanced gastrointestinal stromal tumors and community-acquired bacterial pneumonia. William Liang, Zai Lab's Chief Commercial Officer, emphasized that NHSA reimbursement will expand patient access to these treatments. Both drugs previously received regulatory approval in China, with NUZYRA launched in 2019. GIST affects approximately 30,000 new patients annually in China, highlighting a critical need for effective treatments.
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced the appointment of Michel Vounatsos to its Board of Directors, effective January 7, 2023. Vounatsos has over 25 years of experience in the biopharmaceutical sector, including leadership roles at Biogen and Merck. His extensive commercial background, particularly in neuroscience and operations in China, is expected to enhance Zai Lab's growth and product commercialization efforts. The company currently has four drugs on the market and plans to launch three more, aiming to improve patient care in China and globally.
The LUNAR study by Zai Lab and Novocure has achieved its primary endpoint, showing a statistically significant improvement in overall survival for stage 4 non-small cell lung cancer (NSCLC) patients.
The study demonstrated enhanced survival rates for patients receiving Tumor Treating Fields (TTFields) alongside standard treatments compared to those receiving standard treatments alone. Notably, results indicated a positive trend in survival with TTFields combined with docetaxel. Novocure plans to present the complete findings at an upcoming medical conference and file for FDA approval in late 2023.
Zai Lab Limited (NASDAQ: ZLAB) announced the appointment of Dr. Rafael G. Amado as President and Head of Global Oncology Research and Development, effective December 30, 2022. Dr. Amado, with extensive oncology expertise, previously held leadership roles at Allogene Therapeutics and Adaptimmune. His appointment aims to enhance Zai Lab's oncology R&D capabilities, supporting the company's goal of becoming a leading global biopharmaceutical entity. Dr. Amado's focus will be on accelerating existing and future oncology programs to address unmet medical needs in China and globally.
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced its participation in key investor conferences in January 2023. The company will be present at the Morgan Stanley Virtual China Opportunity Conference from January 4-6, and will present at the J.P. Morgan 41st Annual Healthcare Conference on January 10 at 9:00 a.m. PST in San Francisco. The webcast for the J.P. Morgan conference will be accessible on Zai Lab’s Investor Relations site, with an archived replay available for 30 days. Zai Lab focuses on developing transformative medicines in oncology, autoimmune disorders, infectious diseases, and neurological disorders.
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) presented new interim overall survival (OS) data for ZEJULA® (niraparib) in patients with platinum-sensitive recurrent ovarian cancer at the ESMO Virtual Plenary. The median overall survival was 46.3 months for ZEJULA compared to 43.4 months for placebo. Notably, the results suggest a favorable trend in OS regardless of gBRCA mutation status. No new safety concerns were identified in the study. The final OS analysis is anticipated in 2023, further establishing ZEJULA's role as a second-line maintenance therapy for ovarian cancer.
FAQ
What is the current stock price of Zai Lab American Depositary Shares (ZLAB)?
What is the market cap of Zai Lab American Depositary Shares (ZLAB)?
What does Zai Lab Limited specialize in?
When was Zai Lab Limited founded?
What are some key products in Zai Lab's pipeline?
How does Zai Lab Limited approach drug development?
What recent achievements has Zai Lab Limited made?
Who are the founders of Zai Lab Limited?
What partnerships has Zai Lab Limited established?
Where does Zai Lab Limited conduct clinical development?
Who backs Zai Lab Limited financially?
What is Zai Lab Limited's vision?
